Peter joined IPM as the Head of Venture Capital in 2019, after years of acting as a Strategic Advisor for the Group. Peter is one of the most successful VC investors from the CEE region, with 12 years of experience in both venture and private equity, where he oversaw 8 IPOs in 6 years.
While being responsible for IPM’s overall VC strategy, Peter will also continue fulfilling his remaining responsibilities as Managing Director and Portfolio Manager at Presidio Partners, a multi-sector, deep technology-focused VC fund investing in IT, life sciences, energy and materials. Presidio returned over US$800m in cash to Limited Partners in six years and had eight IPOs with Peter’s direct involvement in five of them.
Peter is an experienced board member, having sat on boards of several companies including Serenova, Corsair Pharma, CNano Technology (sold to Chinese strategic), Arcadia Biosciences (IPO: NASDAQ: RKDA), Reel Solar (acquired by a Chinese strategic), ESS Inc. (Observer), Wildcat Discovery Technologies (Observer), Exela Pharma Sciences (Observer), NeuroRecovery Technologies (Observer), Auspex Pharmaceuticals (Former Observer – IPO: NASDAQ: ASPX and later acquired by Teva for $3.5bn), Ardelyx (Former Observer – IPO: NASDAQ: ARDX), Neos Therapeutics (Former Observer – IPO: NASDAQ: NEOS), SurgiQuest (Former Observer – acquired by ConMed for $265m) and Menlo Therapeutics (Former Observer – IPO: NASDAQ: MNLO).
Previously, Peter worked with SilverLake Kraftwerk and with Warburg Pincus focusing on energy and technology investments. Peter also worked as an Associate at Virgin Green Fund, a private equity fund backed by Sir Richard Branson that provides growth and scale-up capital to companies operating in the renewables and efficiency sectors optimising natural resources in North America, Europe and Israel. Prior to working at Virgin Green Fund, Peter worked in New York as an investment banker at J.P. Morgan.
Peter holds an MBA from the Wharton School, University of Pennsylvania and a BS in Business Administration from the University of North Carolina at Chapel Hill.